Linear Piezoelectric Low Intensity Shockwave Treatment (LI-SWT) for the Treatment of Erectile Dysfunction in PDE5i Non Responder
Linear Piezoelectric Low Intensity Shockwave Treatment (LI-SWT) for the Treatment of Erectile Dysfunction in PDE5i Non Responder: A Randomized-Controlled Trial
The goal of this clinical trial is to assess the efficacy and safety of linear piezoelectric Li-SWT for erectile dysfunction patients who have poor treatment respond from PDE5i oral treatment. Participants will be randomised to either receive 4 cycles, once per week, of Li-SWT treatment on the penis or the Sham group, where the treatment appears to be identical but the shockwave machine is deactivated. Investigators will compare the before and after treatment erectile function using the IIEF questionnaire of the two groups 1 month after treatment to assess the treatment outcome. After that, the Sham group patient would be offered to receive compensatory Li-SWT treatment and their post treatment response will be assessed.
All the patients completing the Li-SWT treatment will be followed up at 6 and 12 months to assess the efficacy and adverse events.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Dr Hung, MBBS
- 電話番号:852-22554852
- メール:hpl826@ha.org.hk
研究場所
-
-
-
Hong Kong、香港
- 募集
- Queen Mary Hospital
-
コンタクト:
- Dr Hung, MBBS
- 電話番号:852-22554852
- メール:hpl826@ha.org.hk
-
主任研究者:
- Pui Long Wilson Hung, MBBS
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Male
- Age 30-80 years
- ED for at least 6 months, defined by IIEF-EF score 8-21 (moderate - mild)
- Sexually active in a stable, heterosexual relationship of more than 3 months duration.
- Agree to comply with all study related tests/procedures
- Morning serum testosterone >12nmol/L
- Inadequate response after at least 4 attempts using highest tolerated PDE5i
Exclusion Criteria:
- Previous penile surgery (e.g. penile lengthening, penile cancer surgery, penile plication, grafting, penile implant).
- Previous history of priapism or penile fracture
- Morning serum testosterone level <12nmol/L
- Current or previous hormone usage, other than prescribed testosterone, clomiphene or thyroid medication. (Subjects with prior or current use of hormonal treatment for prostate cancer are also excluded
- Psychogenic ED as determined by study investigator
- Anatomical (Peyronie's Disease or penile curvature) abnormality
- Neurological disease (Parkinson's, spinal cord injury)
- Anti-coagulation therapy and/or INR >1.5 (Patients on aspirin are eligible) 7
- Current or prior history of sexually transmitted disease
- Tumor tissue/Treatment for cancer in the penile or pelvic region in past 5 years
- Electronic devices implanted in the body (e.g. cardiac pacemaker, deep brain stimulator, spinal cord neurostimulator etc.)
- Any other medical conditions or medical history that are deemed unsafe or high risk for the study treatment per investigator's discretion
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:LiSWT
LiSWT with 8Hz, 0.16 mJ/mm2, wave focus penetration depth 10-15mm at corpora cavernosa (2000 shock), crus of the penis (2000 shock), Once per week for 4 weeks
|
LiSWT with 8Hz, 0.16 mJ/mm2, wave focus penetration depth 10-15mm at corpora cavernosa (2000 shock), crus of the penis (2000 shock), Once per week for 4 weeks
|
|
偽コンパレータ:Sham
Sham comparator with the device deactivated
|
Sham low-intensity shockwave therapy with device deactivated
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of men with improvement in International Index of Erectile Function (IIEF) score at 1 month after traetment
時間枠:1 month after Sham/LiSWT
|
Total scores range from 5 to 25, where higher scores indicate better erectile function/lower severity of erectile dysfunction.
This outcome measure reports the proportion of participants achieving an improvement in IIEF score compared to baseline.
|
1 month after Sham/LiSWT
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of men meeting the Minimal Clinically Important Difference (MCID) in the International Index of Erectile Function (IIEF) score
時間枠:1 month
|
The International Index of Erectile Function (IIEF) is a self-administered questionnaire used to assess erectile function.Total scores range from 5 to 25, where higher scores indicate better erectile function/lower severity of erectile dysfunction.
This outcome measure reports the proportion of participants achieving a minimal clinically important difference (MCID) in the IIEF-5 score compared to baseline.
|
1 month
|
|
Proportion of men meeting the Minimal Clinically Important Difference (MCID) in the International Index of Erectile Function - Erectile Function (IIEF-EF) domain score at 6 and 12 months after treatment
時間枠:6 and 12 months after treatment
|
IIEF is a self-administered questionnaire used to assess erectile function.
Total scores range from 5 to 25, where higher scores indicate better erectile function/lower severity of erectile dysfunction.
This outcome measure reports the proportion of participants achieving a minimal clinically important difference (MCID) in the IIEF-5 score compared to baseline.
|
6 and 12 months after treatment
|
|
Erectile hardness score (EHS) at 1,6, 12 months after treatment
時間枠:1, 6, 12 months after LiSWT treatment
|
vertical score assessing penile hardness on a 4-point single-item scale ranging from 1 to 4, where 1 indicates "penis is larger, but not hard" and 4 indicates "penis is completely hard and fully rigid."
Higher scores indicate better erectile function/rigidity.
|
1, 6, 12 months after LiSWT treatment
|
|
Side effects and safety profile
時間枠:From initiation of first Sham/LiSWT treatment until 12 months after the last LiSWT treatment
|
e.g.
tolerability, pain using the visual analogue scale, bleeding, bruising, penile plaque, penile deformity Safety and tolerability will be evaluated by recording the incidence, severity, and type of all treatment-related adverse events.
Pain will be assessed using a Visual Analogue Scale (VAS), a single-item numeric scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate greater pain intensity.
Specific adverse events evaluated include penile pain, bleeding, bruising, formation of penile plaque, and penile deformity.
|
From initiation of first Sham/LiSWT treatment until 12 months after the last LiSWT treatment
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- LiSWTED
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。